| Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial JS Smolen, A Beaulieu, A Rubbert-Roth, C Ramos-Remus, J Rovensky, ... The Lancet 371 (9617), 987-997, 2008 | 1793 | 2008 |
| Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial J Braun, J Brandt, J Listing, A Zink, R Alten, W Golder, E Gromnica-Lhle, ... The Lancet 359 (9313), 1187-1193, 2002 | 1717 | 2002 |
| Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig JM Kremer, R Westhovens, M Leon, E Di Giorgio, R Alten, S Steinfeld, ... New England Journal of Medicine 349 (20), 1907-1915, 2003 | 1427 | 2003 |
| Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial C Gabay, P Emery, R Van Vollenhoven, A Dikranian, R Alten, K Pavelka, ... The Lancet 381 (9877), 1541-1550, 2013 | 845 | 2013 |
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological … C Ritchlin, P Rahman, A Kavanaugh, IB McInnes, L Puig, S Li, Y Wang, ... Annals of the rheumatic diseases 73 (6), 990-999, 2014 | 743 | 2014 |
| International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis J Braun, T Pham, J Sieper, J Davis, SJ Van der Linden, M Dougados, ... Annals of the rheumatic diseases 62 (9), 817-824, 2003 | 631 | 2003 |
| Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study T Sokka, S Toloza, M Cutolo, H Kautiainen, H Makinen, F Gogus, V Skakic, ... Arthritis research & therapy 11, 1-12, 2009 | 580 | 2009 |
| Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five … LW Moreland, R Alten, F Van Den Bosch, T Appelboom, M Leon, P Emery, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2002 | 495 | 2002 |
| Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised … F Buttgereit, G Doering, A Schaeffler, S Witte, S Sierakowski, ... The Lancet 371 (9608), 205-214, 2008 | 457 | 2008 |
| Physical inactivity in patients with rheumatoid arthritis: data from twenty‐one countries in a cross‐sectional, international study T Sokka, A Häkkinen, H Kautiainen, JF Maillefert, S Toloza, ... Arthritis Care & Research: Official Journal of the American College of …, 2008 | 445 | 2008 |
| Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their … N Schlesinger, RE Alten, T Bardin, HR Schumacher, M Bloch, A Gimona, ... Annals of the rheumatic diseases 71 (11), 1839-1848, 2012 | 415 | 2012 |
| Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study T Sokka, H Kautiainen, T Pincus, SMM Verstappen, A Aggarwal, R Alten, ... Arthritis research & therapy 12, 1-10, 2010 | 386 | 2010 |
| Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three‐month, randomized, placebo‐controlled … J Braun, J Brandt, J Listing, A Zink, R Alten, G Burmester, W Golder, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2003 | 342 | 2003 |
| Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and … R Westhovens, PC Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, ... Annals of the rheumatic diseases 76 (6), 998-1008, 2017 | 268 | 2017 |
| The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis R Alten, H Gram, LA Joosten, WB Berg, J Sieper, S Wassenberg, ... Arthritis research & therapy 10, 1-9, 2008 | 266 | 2008 |
| Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients … J Detert, H Bastian, J Listing, A Weiß, S Wassenberg, A Liebhaber, ... Annals of the rheumatic diseases 72 (6), 844-850, 2013 | 259 | 2013 |
| Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled … J Haschka, M Englbrecht, AJ Hueber, B Manger, A Kleyer, M Reiser, ... Annals of the rheumatic diseases 75 (1), 45-51, 2016 | 258 | 2016 |
| Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years J Braun, X Baraliakos, J Brandt, J Listing, A Zink, R Alten, G Burmester, ... Rheumatology 44 (5), 670-676, 2005 | 244 | 2005 |
| Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ... Arthritis & rheumatology 69 (2), 362-375, 2017 | 238 | 2017 |
| Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate MC Genovese, A Covarrubias, G Leon, E Mysler, M Keiserman, R Valente, ... Arthritis & Rheumatism 63 (10), 2854-2864, 2011 | 237 | 2011 |
Galeazzi MauroProfessore Ordinario di Reumatologia, Università di SienaDirección de correo verificada de unisi.it
